| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:11961216 | IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increase in T3 levels | Metabolic endocrine-mediated perturbations |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg/kg/day | 0.05 mg/kg/day | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Decreased weights of pituitary gland | Neurological endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Alterations in vaginal opening | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Decreased weights of adrenal gland | Metabolic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Decreased liver weights | Hepatic endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Increase in T3 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Increase in TSH levels | Metabolic endocrine-mediated perturbations | |
| IVR | 0.01 mg/kg/day | 0.01 mg/kg/day | Increased weights of thyroid gland | Metabolic endocrine-mediated perturbations | |
| PMID:12383709 | IVR | 0.75 mg/kg/day | 0.75 mg/kg/day | Affects ovulation | Reproductive endocrine-mediated perturbations |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Affects ovulation | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg/day | 5 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg/day | 1 mg/kg/day | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg/day | - | No significant effects observed | - | |
| PMID:12927363 | IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations |
| IVR | 0.03 mg/kg/day | 0.03 mg/kg/day | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.005 mg/kg/day | 0.005 mg/kg/day | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Endometrial atrophy | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Decreased uterine weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Alterations in endometrial morphology | Reproductive endocrine-mediated perturbations | |
| IVR | 0.2 mg/kg/day | 0.2 mg/kg/day | Decreased prostate weights | Reproductive endocrine-mediated perturbations | |
| PMID:15470002 | IVR | 0.05 mg | 0.05 mg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg | 0.05 mg | Decreased estrogen levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.05 mg | 0.05 mg | Atrophy of mammary gland | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00125 mg | 0.00125 mg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.00125 mg | 0.00125 mg | Increased progesterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.00125 mg | 0.00125 mg | Decreased estrogen levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0125 mg | 0.0125 mg | Increased prolactin levels | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0125 mg | 0.0125 mg | Atrophy of mammary gland | Reproductive endocrine-mediated perturbations | |
| IVR | 0.0000125 mg | - | No significant effects observed | - | |
| IVR | 0.000125 mg | - | No significant effects observed | - | |
| IVR | 0.025 mg | 0.025 mg | Atrophy of mammary gland | Reproductive endocrine-mediated perturbations | |
| IVR | 0.025 mg | 0.025 mg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| PMID:24769059 | IVR | 1 mg/kg | 1 mg/kg | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 1 mg/kg | 1 mg/kg | Decreased estradiol levels | Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects ovarian development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1 mg/kg | 1 mg/kg | Affects testis differentiation | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:25584031 | IVR | 0.1 mg | 0.1 mg | Affects folliculogenesis | Reproductive endocrine-mediated perturbations |
| IVR | 0.1 mg | 0.1 mg | Decreased ovarian weights | Reproductive endocrine-mediated perturbations | |
| PMID:26304810 | IVR | 75 mg/kg | 75 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations |
| IVR | 75 mg/kg | 75 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 225 mg/kg | 225 mg/kg | Affects developmental process | Developmental endocrine-mediated perturbations | |
| IVR | 225 mg/kg | 225 mg/kg | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| PMID:27395752 | IVR | 10 mg/kg | 10 mg/kg | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations |
| IVR | 10 mg/kg | 10 mg/kg | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:28827578 | IVR | 250 mg/L | 250 mg/L | Undescended testes (or cryptorchidism) | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 250 mg/L | 250 mg/L | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/L | 1000 mg/L | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/L | 1000 mg/L | Undescended testes (or cryptorchidism) | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 1000 mg/L | 1000 mg/L | Alterations in number of sertoli cells | Reproductive endocrine-mediated perturbations | |
| IVR | 3000 mg/L | 3000 mg/L | Alterations in number of sertoli cells | Reproductive endocrine-mediated perturbations | |
| IVR | 3000 mg/L | 3000 mg/L | Affects spermatogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 3000 mg/L | 3000 mg/L | Undescended testes (or cryptorchidism) | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.